A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis

About

Brief Summary

The purpose of this study is to determine the safety and efficacy of brepocitinib in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).

Primary Purpose

Treatment

Study Type

Interventional

Phase

Phase 3

Eligibility

Gender

All

Healthy Volunteers

No

Minimum Age

18 Years

Maximum Age

75 Years

Inclusion Criteria:

Adult subjects (18-75 years old)
Diagnosis of non-infectious uveitis (intermediate uveitis, posterior uveitis, or panuveitis)
Active uveitic disease in at least 1 eye
Weight > 40 kg with a body mass index ≤ 40 kg/m2

Exclusion Criteria:

Has confirmed or suspected current diagnosis of infectious uveitis History of or have:

Lymphoproliferative disorder
active malignancy
cancer within 5 years prior to screening (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid carcinoma.)
thrombosis orand cerebrovascularardiovascular ischemic event disease within the last 12 months
a high risk for herpes zoster reactivation
active or recent infections

Not a fit? Find another study